Sarepta Therapeutics Inc (NASDAQ: SRPT) has reported earnings for its fourth fiscal quarter (ending December 31) of $1.65 versus $0.49 for the same period a year ago — an increase of 237%. For the latest four quarters through December 31, E.P.S. were $2.47 versus $-5.80 for the same period a year ago — a decline of -143%.
Recent Price Action
Sarepta Therapeutics Inc (NASDAQ: SRPT) stock declined slightly by -0.08% on 2/26/25. The stock closed at $106.86. Moreover, trading volume in this decline was above average at 135% of normal. Relative to the market the stock has been weak over the last nine months but has risen 1.4% during the last week.
Current PriceTarget Research Rating
Sarepta Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Sarepta Therapeutics has a very high Appreciation Score of 91 but a very low Power Rating of 13, triggering the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment